Intelligence Platform
Patents
Browse 774 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted patentUS 12415863
Compositions and methods for treating cancer
granted patentUS 12403192
Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflamma
granted patentUS 12397058
Metabolically stable prodrugs
granted patentUS 12390427
Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
granted patentUS 12377051
Microspheres for extended, controlled release of therapeutic agents
granted patentUS 12364688
NSD family inhibitors and methods of treatment therewith
granted patentUS 12364736
Methods for treating heterotopic ossification
granted patentUS 12329882
Aligned hydrogel tubes for tissue repair and regeneration
granted patentUS 12329827
Devices, compositions and related methods for accelerating and enhancing bone repair
granted patentUS 12324843
Compositions and methods for delivery of biomacromolecule agents
granted patentUS 12319703
Macrocyclic fused pyrazoles as Mcl-1 inhibitors
granted patentUS 12296048
Polymer particles for neutrophil injury
granted patentUS 12285490
ASH1L degraders and methods of treatment therewith
granted patentUS 12280159
Therapeutic protein-based nanoparticles for treating cancer
granted patentUS 12270080
NcRNA and uses thereof
granted patentUS 12257352
Compositions and methods for delivery of biomacromolecule agents
granted patentUS 12258425
Peptide compositions and methods of use
granted patentUS 12252714
Halogenation of complex organic compounds
granted patentUS 12246056
Compositions and methods for the production of cysteine
granted patentUS 12240852
Co-crystals, method and apparatus for forming the same
granted patentUS 12233063
Compositions and methods for treating eye disorders
granted patentUS 12233150
Oral care compositions comprising star-shaped polymers
granted patentUS 12226524
Coated implants for long-term controlled release of antibody therapeutics
granted